Young-Kwang Yoon

发表

Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells.

Y. Bang, S. Im, D. Oh, 2012, Cancer Letters.

Expedited Safety Reporting Through an Alert System for Clinical Trial Management at an Academic Medical Center: Retrospective Design Study

Y. Park, H. Kim, S. Baek, 2020, JMIR medical informatics.

Chemical Therapeutics Discovery & Preclinical Development Antitumor Activity of Saracatinib ( AZD 0530 ) , a cSrc / Abl Kinase Inhibitor , Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Y. Bang, P. Elvin, S. Im, 2013 .

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Y. Bang, P. Elvin, S. Im, 2012, Molecular Cancer Therapeutics.

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Y. Bang, M. O’Connor, S. Im, 2013, Molecular Cancer Therapeutics.

The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

Y. Bang, S. Im, D. Oh, 2012, Investigational New Drugs.

Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells

Young-Kwang Yoon, Tae-You Kim, Hye-Jin Kim, 2012, Anti-cancer drugs.

Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers

Y. Bang, S. Im, D. Oh, 2012, Laboratory Investigation.

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer

Tae Won Kim, S. Jang, Dalyong Kim, 2017, BMC Gastroenterology.

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.

Jin Won Kim, Young-Kwang Yoon, Tae-You Kim, 2008, Cancer letters.

Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS

Deokhoon Kim, Tae Won Kim, S. Jang, 2018, Translational oncology.

Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer.

Y. Bang, S. Im, W. Kim, 2012, Cancer letters.

HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild‐type RAS and BRAF

Deokhoon Kim, Tae Won Kim, S. Jang, 2017, Clinical colorectal cancer.

Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.

Young-Kwang Yoon, Tae-You Kim, Hyun-Jin Nam, 2011, Cancer letters.

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

Young-Kwang Yoon, Tae-You Kim, Y. Bang, 2010, Molecular carcinogenesis.

Chemical Therapeutics RAD 51 CDe fi cient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Y. Bang, M. O’Connor, S. Im, 2013 .

Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center

Sang Min Lee, Tae Won Kim, S. Jang, 2019, PloS one.

Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody

K. Kang, Y. Bang, E. Yi, 2012, PloS one.

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Y. Bang, S. Im, D. Oh, 2009, Molecular Cancer Therapeutics.

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.

Ju-Hee Lee, Y. Bang, S. Im, 2010, Cancer letters.

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2

Young-Kwang Yoon, Tae-You Kim, Ju-Hee Lee, 2009, PloS one.

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

Y. Bang, S. Im, D. Oh, 2010, Molecular carcinogenesis.

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Y. Bang, P. Elvin, S. Im, 2012, Molecular Cancer Therapeutics.

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.

Y. Bang, S. Im, J. W. Kim, 2008, Cancer letters.